Literature DB >> 9056596

Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?

L F Lacey1, O N Keene, J F Pritchard, A Bye.   

Abstract

We investigated the hypothesis that distributions of continuous pharmacokinetic variables are positively skewed in nature and that logarithmic transformation of these variables restores normality. The distributions of common continuous noncompartmental pharmacokinetic variables were investigated for four different Glaxo Wellcome compounds, administered by three different routes of administration: ranitidine (po), sumatriptan (sc), ondansetron (iv), and bismuth, from ranitidine bismuth citrate (po). The distributions of all the investigated noncompartmental pharmacokinetic variables were adequately described by a log-normal distribution, whereas statistically significant departures from normality occurred in the majority of cases. Thus, unless there is strong and consistent evidence for a departure from log-normality, the parametric statistical analysis of common noncompartmental pharmacokinetic variables should be carried out after a priori log transformation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056596     DOI: 10.1080/10543409708835177

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  34 in total

1.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

Authors:  David M Peereboom; Jeffrey G Supko; Kathryn A Carson; Tracy Batchelor; Surasak Phuphanich; Glenn Lesser; Tom Mikkelsen; Tom Mikkelson; Joy Fisher; Serena Desideri; Xiaoying He; Stuart A Grossman
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

3.  Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.

Authors:  L B Nabors; J G Supko; M Rosenfeld; M Chamberlain; S Phuphanich; T Batchelor; S Desideri; X Ye; J Wright; S Gujar; S A Grossman
Journal:  Neuro Oncol       Date:  2011-09-27       Impact factor: 12.300

4.  The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube.

Authors:  Gregory Podilsky; Markoulina Berger-Gryllaki; Bernard Testa; Thierry Buclin; Michel Roulet; Andre Pannatier
Journal:  Eur J Clin Pharmacol       Date:  2009-02-03       Impact factor: 2.953

5.  Comparison of parametric and bootstrap method in bioequivalence test.

Authors:  Byung-Jin Ahn; Dong-Seok Yim
Journal:  Korean J Physiol Pharmacol       Date:  2009-10-31       Impact factor: 2.016

6.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

7.  Sample size determination in bioequivalence studies using statistical assurance.

Authors:  A Ring; B Lang; C Kazaroho; D Labes; R Schall; H Schütz
Journal:  Br J Clin Pharmacol       Date:  2019-08-13       Impact factor: 4.335

8.  A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects.

Authors:  Chris Wynne; Christian Schwabe; Sonica Sachdeva Batra; Luis Lopez-Lazaro; Suresh Kankanwadi
Journal:  Br J Clin Pharmacol       Date:  2018-07-26       Impact factor: 4.335

9.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:  David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

10.  Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.

Authors:  Stuart A Grossman; Jeffrey Olson; Tracy Batchelor; David Peereboom; Glenn Lesser; Serena Desideri; Xiaobu Ye; Tarek Hammour; Jeffrey G Supko
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.